Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors

Non-small cell lung cancer (NSCLC) driven by activating mutations in epidermal growth factor receptor (EGFR) constitutes up to 10% of NSCLC cases. According to the NCCN recommendations, all patients (with the exception of smoking patients with squamous cell lung cancer) should be screened for the pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Skrzypski, Marcin, Szymanowska-Narloch, Amelia, Dziadziuszko, Rafał
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701587/
https://www.ncbi.nlm.nih.gov/pubmed/29180936
http://dx.doi.org/10.5114/wo.2017.70116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701587/
https://www.ncbi.nlm.nih.gov/pubmed/29180936
http://dx.doi.org/10.5114/wo.2017.70116

Ejemplares similares